Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Genfit S.A.
Genfit S.A. News
Genfit S.A. Quantitative Score
About Genfit S.A.
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.
Genfit S.A. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Genfit S.A. Financials
Table Compare
Compare GNFT metrics with: | |||
|---|---|---|---|
Earnings & Growth | GNFT | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | GNFT | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | GNFT | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | GNFT | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Genfit S.A. Income
Genfit S.A. Balance Sheet
Genfit S.A. Cash Flow
Genfit S.A. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Sell |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Genfit S.A. Executives
| Name | Role |
|---|---|
| Dr. Dean W. Hum Ph.D. | Chief Scientific Officer |
| Mr. M. Pascal Prigent | Chief Executive Officer |
| Mr. Jean-Francois Mouney | Co-Founder & Chairman of the Board |
| Mr. Laurent Lannoo | Corporate Secretary & Director of Legal Affairs |
| Prof. Bart Staels | Co-Founder & Chairman of the Scientific Advisory Board |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Dr. Dean W. Hum Ph.D. | Chief Scientific Officer | 1962 | 798.27K | |
| Mr. M. Pascal Prigent | Chief Executive Officer | Male | 1969 | 699.35K |
| Mr. Jean-Francois Mouney | Co-Founder & Chairman of the Board | Male | 1955 | 429.83K |
| Mr. Laurent Lannoo | Corporate Secretary & Director of Legal Affairs | Male | 1971 | -- |
| Prof. Bart Staels | Co-Founder & Chairman of the Scientific Advisory Board | 1963 | -- |